BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/15/2023 4:42:25 AM | Browse: 427 | Download: 1122
Publication Name World Journal of Transplantation
Manuscript ID 83833
Country United States
ISSN 2220-3230 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Transplantation
Manuscript Type Minireviews
Article Title Sodium-glucose cotransporter-2 inhibitor use in kidney transplant recipients
Manuscript Source Invited Manuscript
All Author List Pavithra Ramakrishnan, Neetika Garg, Samantha Pabich, Didier A Mandelbrot and Kurtis J Swanson
ORCID
Author(s) ORCID Number
Neetika Garg http://orcid.org/0000-0002-7392-4285
Samantha Pabich http://orcid.org/0000-0003-3169-8942
Didier A Mandelbrot http://orcid.org/0000-0003-3326-8583
Kurtis J Swanson http://orcid.org/0000-0001-5952-9054
Funding Agency and Grant Number
Corresponding Author Kurtis J Swanson, MD, Assistant Professor, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Highland Ave Madison, Madison, WI 53705, United States. kswanson@medicine.wisc.edu
Key Words Sodium glucose cotransporter-2; Sodium glucose cotransporter-2 inhibitor; Kidney transplantation; Diabetes; Post-transplant diabetes mellitus; New onset diabetes after transplant
Core Tip Multiple large trials have demonstrated sodium-glucose cotransporter-2 inhibitors (SGLT2i) associated kidney and cardiovascular benefits for chronic kidney disease patients with diabetes. Important considerations are critical to determine safety and efficacy of these medications after kidney transplantation. While evidence is limited, SGLT2i appear to be both safe and effective short-term. More robust research is needed to determine the long-term impacts of their use in kidney transplant recipients. Appropriate patient selection and monitoring are vital to clinical use and future research efforts of SGLT2i in kidney transplantation.
Publish Date 2023-09-15 04:42
Citation Ramakrishnan P, Garg N, Pabich S, Mandelbrot DA, Swanson KJ. Sodium-glucose cotransporter-2 inhibitor use in kidney transplant recipients. World J Transplant 2023; 13(5): 239-249
URL https://www.wjgnet.com/2220-3230/full/v13/i5/239.htm
DOI https://dx.doi.org/10.5500/wjt.v13.i5.239
Full Article (PDF) WJT-13-239-with-cover.pdf
Full Article (Word) WJT-13-239.docx